This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

CD30 in Lymphoma: An Increasingly Important Role in Testing and Targeting

CD30 in Lymphoma: An Increasingly Important Role in Testing and Targeting

Format

Webcast

Time to Complete

1 hour

Released

January 3, 2017

Expires

January 3, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CE for Nurse Practitioners (0.30 pharmacology hours)

Accredited Provider

This activity is provided by Global Education Group. Paradigm Medical Communications, LLC is the educational partner.

Commercial Supporter

This activity is supported by an educational grant from Seattle Genetics, Inc.

Program Description

During this webinar, a national expert in the management of patients with CD30-positive lymphomas discusses the spectrum of CD30-positive lymphomas; when CD30 testing should be performed; the role of the pathologist in the management of CD30-positive lymphomas; the mechanism of action of antibody-drug conjugates and their clinical relevance; safety and efficacy profiles of antibody-drug conjugates; and key data from late-phase clinical trials. An animated mechanism-of-action video is included to depict the antibody-drug conjugates used in the treatment of CD30-positive lymphomas. The activity also includes several diagnostic and treatment case scenarios.

Intended Audience

This activity has been designed to address the educational needs of physicians, PAs, and nurse practitioners within the specialties of oncology, hematology, hematology/oncology, and pathology. This activity will also be of benefit to other healthcare providers interested in the management of patients with CD30-positive lymphomas, including pharmacists and oncology nurses.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Review the role of CD30 testing in the diagnosis of each of the subtypes of CD30-positive lymphomas
  • Describe the role of the pathologist in diagnosing CD30-positive lymphomas and the tests used in CD30 determination
  • Explain the utility of CD30-targeted antibody drug conjugates in treating CD30-positive lymphomas based on the mechanism of action, efficacy, toxicities, and late-phase clinical trial results

Conflict Of Interest Disclosure Policy

Global Education Group (Global) and Paradigm Medical Communications, LLC (Paradigm) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global and Paradigm for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty
Steven M. Horwitz, MD

Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Horwitz has the following financial relationships to disclose:

Grant/Research Support: Celgene Corporation; Infinity Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; Millennium Pharmaceuticals, Inc; Seattle Genetics, Inc; Spectrum Pharmaceuticals, Inc

Retained Consultant: Amgen Inc; Bristol-Myers Squibb Company; Celgene Corporation; Millennium Pharmaceuticals, Inc; Seattle Genetics, Inc; Spectrum Pharmaceuticals, Inc

Honoraria: Amgen Inc; Bristol-Myers Squibb Company; Celgene Corporation; Millennium Pharmaceuticals, Inc; Seattle Genetics, Inc; Spectrum Pharmaceuticals, Inc

Other (Travel): ADC Therapeutics

Ratesh Khillan, MD
Interfaith Medical Center
Brooklyn, NY

Dr. Khillan has no financial relationships to disclose.

Steering Committee
Steven T. Rosen, MD (Chair)

Provost and Chief Scientific Officer
Director, Comprehensive Cancer Center and Beckman Research Institute
Irell & Manella Cancer Center Director’s Distinguished Chair
City of Hope
Duarte, CA

Dr. Rosen has no financial relationships to disclose.

Keri A. Halsema, NP
Nurse Practitioner
Hematology-Oncology/Bone Marrow Transplant Department
University of Colorado Hospital
Aurora, CO

Ms. Halsema has no financial relationships to disclose.

Eric D. Hsi, MD
Professor of Pathology
Cleveland Clinic Lerner College of Medicine
Section Head, Hematopathology
Chair, Department of Laboratory Medicine
Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland Clinic
Cleveland, OH

Dr. Hsi has the following financial relationships to disclose:

Research Support: AbbVie Inc.; Cellerant Therapeutics, Inc.; Eli Lilly and Company

Advisory Board: Celgene Corporation; HTG Molecular Diagnostics, Inc.

Honoraria: Seattle Genetics, Inc

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Amanda Glazer, PhD, Kristen Delisi, and Laura Gilsdorf have no financial relationships to disclose.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Designation Statement

Global Education Group designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

Credit

1.00

Type

CE for Nurse Practitioners

Accreditation Statement



Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121.

For information about the accreditation of this program, please contact Global at (303) 395-1782 or inquire@globaleducationgroup.com.

Designation Statement

This activity is accredited for 1.00 contact hour(s) which includes 0.30 hour(s) of pharmacology.
Activity ID #2137E.

This activity was planned in accordance with AANP CE Standards and Policies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Paradigm do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.

Instructions

To receive a CE certificate of participation, participants must:

  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pretest.
  • View the online activity in its entirety.
  • Complete and submit the online post-test and evaluation. You must answer 70% of the post-test questions correctly to earn credit. You will have unlimited opportunities to successfully complete the post-test.
A certificate of participation will be available for download/printing immediately following your successful completion of the post-test and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.

There is no fee required for participation in this activity.

For questions regarding CE credit, contact the Paradigm CME Department at (845) 398-5949.

Technical Support: If you have any technical problems or playback issues, please email Paradigm at contactus@paradigmmc.com.

Privacy Policy

Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Global Education Group or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Global or Paradigm. Global and Paradigm accept no liability for the content referenced in this activity.

Privacy policy
Global and Paradigm are committed to protecting the privacy of those who participate in the activities (herein referred to as “website”) located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Global and Paradigm to continuously improve the learning experience.

Global Education Group and Paradigm Medical Communications, LLC do not transfer, sell, or share personal information with outside parties. Global Education Group and Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Global and Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.

myCME privacy policy

System Requirements

This certified CE activity is designed using HTML5 video and audio.

For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Copyright

© 2017 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Add to Queue